IL311639A - Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders - Google Patents
Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disordersInfo
- Publication number
- IL311639A IL311639A IL311639A IL31163924A IL311639A IL 311639 A IL311639 A IL 311639A IL 311639 A IL311639 A IL 311639A IL 31163924 A IL31163924 A IL 31163924A IL 311639 A IL311639 A IL 311639A
- Authority
- IL
- Israel
- Prior art keywords
- antigen
- binding fragment
- cognitive
- assessment
- disease
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title claims 13
- 238000000034 method Methods 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 239000012634 fragment Substances 0.000 claims 28
- 208000010877 cognitive disease Diseases 0.000 claims 23
- 108010056102 CD100 antigen Proteins 0.000 claims 18
- 102100027744 Semaphorin-4D Human genes 0.000 claims 18
- 230000001149 cognitive effect Effects 0.000 claims 16
- 208000028698 Cognitive impairment Diseases 0.000 claims 13
- 208000023105 Huntington disease Diseases 0.000 claims 13
- 230000009760 functional impairment Effects 0.000 claims 10
- 208000027061 mild cognitive impairment Diseases 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 4
- 206010003591 Ataxia Diseases 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 102100034384 Plexin-B1 Human genes 0.000 claims 3
- 101710100559 Plexin-B1 Proteins 0.000 claims 3
- 102100034383 Plexin-B2 Human genes 0.000 claims 3
- 101710100551 Plexin-B2 Proteins 0.000 claims 3
- 208000011235 central nervous system lupus Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1124—Determining motor skills
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/168—Evaluating attention deficit, hyperactivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2505/00—Evaluating, monitoring or diagnosing in the context of a particular type of medical care
- A61B2505/09—Rehabilitation or training
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Developmental Disabilities (AREA)
- Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Educational Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Artificial Intelligence (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Signal Processing (AREA)
- Genetics & Genomics (AREA)
- Social Psychology (AREA)
Claims (42)
1. A method of selecting subjects having, determined to have, or suspected of having a neurodegenerative disorder for treatment with an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D), said method comprising: (i) determining the cognitive and/or functional impairment assessment score for the subject in one or more standard cognitive and/or functional assessment tests; and (ii) selecting the subject for treatment if the score satisfies a predetermined value indicative of mild cognitive impairment (MCI), mild dementia, moderate cognitive impairment, or Stage I or Stage II Huntington’s disease.
2. The method of claim 1, wherein the one or more standard cognitive assessment and/or functional assessment tests are selected from the Montreal Cognitive Assessment (MoCA), the Total Functional Capacity (TFC), Clinical Global Impression of Change (CGIC), and the Clinical Global Impression of Severity (CGIS).
3. The method of claim1 or 2, wherein the one or more standard functional assessment test is the TFC and wherein the functional impairment assessment score for the subject is in the range of 7-12.
4. The method of claim 3, wherein the functional impairment assessment score for the subject is in the range of 8-12 or 8-11.
5. The method of claim 1 or 2, wherein the one or more standard cognitive assessment test is the MoCA and wherein the cognitive impairment assessment score for the subject is in the range of from 10-25.
6. The method of claim 5, wherein the MoCA score is in the range of from 19-25.
7. The method of claim 5, wherein the MoCA score is in the range of from 11-21.
8. The method of any one of claims 1-7, wherein the neurodegenerative disorder is selected from a group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, Down syndrome, ataxia, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), HIV-related cognitive impairment, CNS Lupus, mild cognitive impairment to moderate cognitive impairment, or a combination thereof.
9. The method of claim 8, wherein the neurodegenerative disorder is Alzheimer’s disease (AD) or Huntington’s disease (HD).
10. The method of any one of claims 1-9, wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively, or comprises a - 47 - variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 42, 43, and 44, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 46, 47, and 48, respectively.
11. The method of any one of claims 1-10, wherein the antibody or antigen binding fragment thereof inhibits SEMA4D binding to its receptor.
12. The method of claim 11, wherein the receptor is selected from Plexin-B1 and Plexin-B2.
13. The method of claim 11or 12, wherein the antibody or antigen binding fragment thereof inhibits SEMA4D-mediated signal transduction.
14. A method for predicting whether a semaphorin-4D (SEMA4D) antagonist antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D will be effective in treating a subject having, diagnosed as having, or suspected of having a neurodegenerative disorder, comprising: (i) determining the cognitive and/or functional impairment assessment score for the subject in one or more standard cognitive and/or functional assessment tests; and (ii) predicting a positive response to treatment if the score satisfies a predetermined value indicative of mild cognitive impairment (MCI), mild dementia, moderate cognitive impairment or Stage I or Stage II Huntington’s disease.
15. The method of claim 14, wherein the one or more standard cognitive and/or functional assessment tests are selected from the Montreal Cognitive Assessment (MoCA), the Total Functional Capacity (TFC), Clinical Global Impression of Change (CGIC), and the Clinical Global Impression of Severity (CGIS).
16. The method of claim 14 or 15, wherein the standard functional assessment test is the TFC and wherein the functional impairment assessment score for the subject is in the range of 7-12.
17. The method of claim 16, wherein the functional impairment assessment score for the subject s in the range of 8-12 or 8-11.
18. The method of claim 14 or 15, wherein the standard cognitive assessment test is the MoCA and wherein the cognitive impairment assessment score for the subject is in the range of from 10-25.
19. The method of claim 18, wherein the MoCA score is in the range of from 19-25.
20. The method of claim 18, wherein the MoCA score is in the range of from 11-21.
21. The method of any one of claims 14-20, wherein the neurodegenerative disorder is selected from a group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, Down syndrome, ataxia, amyotrophic lateral sclerosis (ALS), frontotemporal - 48 - dementia (FTD), HIV-related cognitive impairment, CNS Lupus, mild cognitive impairment to moderate cognitive impairment, or a combination thereof.
22. The method of claim 21, wherein the neurodegenerative disorder is Alzheimer’s disease (AD) or Huntington’s disease (HD).
23. The method of any one of claims 14-22, wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively or comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 42, 43, and 44, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 46, 47, and 48, respectively.
24. The method of any one of claims 14-23, wherein the antibody or antigen binding fragment thereof inhibits SEMA4D binding to its receptor.
25. The method of claim 24, wherein the receptor is selected from Plexin-B1 and Plexin-B2.
26. The method of claim 24 or 25, wherein the antibody or antigen binding fragment thereof inhibits SEMA4D-mediated signal transduction.
27. An isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) for use in a method of treating a subject having, determined to have, or suspected of having a neurodegenerative disorder, the method comprising (i) determining the cognitive and/or functional impairment assessment score for the subject in one or more standard cognitive and/or functional assessment tests; and (ii) administering a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof if the score satisfies a predetermined value indicative of mild cognitive impairment (MCI), mild dementia, moderate cognitive impairment or Stage I or Stage II Huntington’s disease.
28. The isolated antibody or antigen-binding fragment thereof for use of claim 27, wherein the one or more standard cognitive or functional assessment tests are selected from the Montreal Cognitive Assessment (MoCA), the Total Functional Capacity (TFC), Clinical Global Impression of Change (CGIC), and the Clinical Global Impression of Severity (CGIS).
29. The isolated antibody or antigen-binding fragment thereof for use of claim 27 or 28, wherein the standard functional assessment test is the TFC and wherein the functional impairment assessment score for the subject is in the range of 7-12.
30. The isolated antibody or antigen-binding fragment thereof for use of claim 28, wherein the functional impairment assessment score for the subject is in the range of 8-12 or 8-11. - 49 -
31. The isolated antibody or antigen-binding fragment thereof for use of claim 27 or 28, wherein the standard cognitive assessment test is the MoCA and wherein the cognitive impairment assessment score for the subject is in the range of from 10-25.
32. The isolated antibody or antigen-binding fragment thereof for use of claim 31, wherein the MoCA score is in the range of from 19-25.
33. The isolated antibody or antigen-binding fragment thereof for use of claim 31, wherein the MoCA score is in the range of from 11-21.
34. The isolated antibody or antigen-binding fragment thereof for use of any one of claims 27-33, wherein the neurodegenerative disorder is selected from a group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, Down syndrome, ataxia, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), HIV-related cognitive impairment, CNS Lupus, mild cognitive impairment, or a combination thereof.
35. The isolated antibody or antigen-binding fragment thereof for use of claim 34, wherein the neurodegenerative disorder is Alzheimer’s disease (AD) or Huntington’s disease (HD).
36. The isolated antibody or antigen-binding fragment thereof for use of any one of claims 27-35, wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-comprising SEQ ID NOs 14, 15, and 16, respectively or comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 42, 43, and 44, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 46, 47, and 48, respectively.
37. The isolated antibody or antigen-binding fragment thereof for use of any one of claims 27-36, wherein the antibody or antigen binding fragment thereof inhibits SEMA4D binding to its receptor.
38. The isolated antibody or antigen-binding fragment thereof for use of claim 37, wherein the receptor is selected from Plexin-B1 and Plexin-B2.
39. The isolated antibody or antigen-binding fragment thereof for use of claim 37 or 38, wherein the antibody or antigen binding fragment thereof inhibits SEMA4D-mediated signal transduction.
40. The isolated antibody or antigen-binding fragment thereof for use of any one of claims 27-39, wherein the treatment results in a decrease, reduction, slowing or stopping of the incidence of symptoms associated with the neurodegenerative disorder; a decrease, reduction or lessening of the severity of symptoms associated with the neurodegenerative disorder; or improves the quality of life of the subject. - 50 -
41. The isolated antibody or antigen-binding fragment thereof for use of claim 40, wherein the symptoms are selected from neuropsychiatric symptoms, cognitive symptoms, motor dysfunction and any combination thereof.
42. An isolated antibody or antigen-binding fragment thereof which specifically binds to semaphorin-4D (SEMA4D) for use in a method of treating a subject that has, is suspected of having or is diagnosed with a neurodegenerative disorder, wherein the subject is assessed to have a cognitive impairment assessment score in one or more standard cognitive assessment tests that is indicative of mild cognitive impairment, mild dementia or moderate cognitive impairment or is assessed to have a functional impairment assessment score in one or more standard functional assessment tests that is indicative of Stage I or Stage II Huntington’s disease.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/052142 WO2023048726A1 (en) | 2021-09-27 | 2021-09-27 | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311639A true IL311639A (en) | 2024-05-01 |
Family
ID=78463919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311639A IL311639A (en) | 2021-09-27 | 2021-09-27 | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
Country Status (5)
| Country | Link |
|---|---|
| KR (1) | KR20240063995A (en) |
| AU (1) | AU2021465518A1 (en) |
| CA (1) | CA3231551A1 (en) |
| IL (1) | IL311639A (en) |
| WO (1) | WO2023048726A1 (en) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
| FR2686087A1 (en) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | NOVEL LYMPHOCYTATIC ANTIGEN, CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP4095753B2 (en) | 2000-03-30 | 2008-06-04 | 株式会社ルネサステクノロジ | Computer-readable storage medium and semiconductor device design method |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| EA025245B1 (en) | 2009-05-08 | 2016-12-30 | Вэксинекс, Инк. | Anti-cd100 antibodies and methods for using the same |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| BR112019017367A2 (en) * | 2017-02-22 | 2020-04-14 | Vaccinex Inc | early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| CN110636858B (en) | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | Human anti-semaphorin 4D antibodies |
-
2021
- 2021-09-27 AU AU2021465518A patent/AU2021465518A1/en active Pending
- 2021-09-27 CA CA3231551A patent/CA3231551A1/en active Pending
- 2021-09-27 KR KR1020247013488A patent/KR20240063995A/en active Search and Examination
- 2021-09-27 IL IL311639A patent/IL311639A/en unknown
- 2021-09-27 WO PCT/US2021/052142 patent/WO2023048726A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021465518A1 (en) | 2024-05-02 |
| WO2023048726A1 (en) | 2023-03-30 |
| KR20240063995A (en) | 2024-05-10 |
| CA3231551A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maanen et al. | The α7 nicotinic acetylcholine receptor on fibroblast‐like synoviocytes and in synovial tissue from rheumatoid arthritis patients: a possible role for a key neurotransmitter in synovial inflammation | |
| Huijbers et al. | The expanding field of IgG4‐mediated neurological autoimmune disorders | |
| Morisaki et al. | Selective expression of osteopontin in ALS-resistant motor neurons is a critical determinant of late phase neurodegeneration mediated by matrix metalloproteinase-9 | |
| Helmstaedter et al. | Disentangling the relationship between epilepsy and its behavioral comorbidities—the need for prospective studies in new-onset epilepsies | |
| JP2017502920A5 (en) | ||
| IL275720B (en) | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders | |
| JP2019059786A5 (en) | ||
| RU2019122337A (en) | EARLY DETECTION OF GLIAL CELL ACTIVATION IN NEURODEGENERATIVE OR NEUROINFLAMMATORY DISEASES | |
| US11022618B2 (en) | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43 | |
| JP2020510845A5 (en) | ||
| RU2014144331A (en) | HUMANIZED TAU ANTIBODY | |
| JP5785873B2 (en) | T cell activation inhibitor, pharmaceutical composition containing the same, and screening method for T cell activation inhibitor | |
| Das et al. | CCL20-CCR6 axis modulated traumatic brain injury-induced visual pathologies | |
| Qin et al. | Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients | |
| Balestra et al. | Antibodies against neuronal nicotinic receptor subtypes in neurological disorders | |
| IL311639A (en) | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders | |
| Hüfner et al. | Neurology issues in schizophrenia | |
| Hermosillo-Romo et al. | Neuropsychiatric involvement in systemic lupus erythematosus | |
| Hanaoka et al. | Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV | |
| Gupta et al. | Growing spectrum of autoimmune nodopathies | |
| Cervantes González et al. | Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration | |
| Estades Ayuso et al. | TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains | |
| Yamakawa et al. | Antibodies to the α3 subunit of the ganglionic-type nicotinic acetylcholine receptors in patients with autoimmune encephalitis | |
| Zhou et al. | Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosis | |
| Rabaneda-Lombarte et al. | Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinson’s disease patients |